A case of surgical resection complete pathological response after neoadjuvant immunotherapy for microsatellite instability-high colon cancer

doi:10.3877/cma.j.issn.1674-0785.2021.11.019

Chinese Journal of Clinicians(Electronic Edition) ›› 2021, Vol. 15 ›› Issue (11): 911-914. doi: 10.3877/cma.j.issn.1674-0785.2021.11.019

• Case Report • Previous Articles Next Articles

A case of surgical resection complete pathological response after neoadjuvant immunotherapy for microsatellite instability-high colon cancer

Jinhua Tao¹, Zhuo Liu¹, Dening Ma¹

Received:2021-07-26 Online:2021-11-15 Published:2022-03-18

Abstract

Jinhua Tao, Zhuo Liu, Dening Ma. A case of surgical resection complete pathological response after neoadjuvant immunotherapy for microsatellite instability-high colon cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(11): 911-914.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2021.11.019

https://zhlcyszz.cma-cmc.com.cn/EN/Y2021/V15/I11/911

Figures/Tables 4

References 6

1	Dung TL, Tae WK, Eric VC, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164 [J]. J Clin Oncol, 2020, 38(1): 11-19.
2	Michael JO, Ray MD, Joseph LL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study [J]. Lancet Oncol, 2017, 18(9): 1182-1191.
3	Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 Study [J]. JAMA Oncol, 2020, 6(6): 831-838.
4	Chalabi M, Fanchi LF, Van den Berg JG, et al. LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage coloc cancer [J]. Ann Oncol, 2018, 29(Suppl 8): 11-12.
5	Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers [J]. Nat Med, 2020, 26(4): 566-576.
6	Karki S, Umar S, Kasi A. Treating colorectal cancer with immunotherapy: implications for single versus combination therapy [J]. Curr Colorectal Cancer Rep, 2020, 16(5): 107-117.

检测项目	检测内容	检测意义	检测结果
体细胞基因变异检测	830个基因点突变、缺失、插入分析，44个基因重排分析，88个基因拷贝数分享	预测靶向药物的有效性、肿瘤分子分型、判断预后	99个基因突变，未见基因重排，未见基因拷贝数变异
肿瘤突变负荷（TMB）	830个基因点突变、缺失、插入分析	预测免疫治疗药物疗效	51.64 muts/Mb
微卫星不稳定性（MSI）	3009个微卫星位点（MS）	预测免疫治疗药物疗效	微卫星不稳定型（MSI-H）
化疗单核苷酸多态性（SNP）位点检测	45个SNP位点	预测常见化疗药物有效性和毒副作用	详见检测结果详细解析
肿瘤遗传易感基因检测	148个肿瘤遗传易感基因	预测多种肿瘤的遗传风险	未检测到与肿瘤遗传易感性相关的明确致病突变

检测项目	检测内容	检测意义	检测结果
体细胞基因变异检测	830个基因点突变、缺失、插入分析，44个基因重排分析，88个基因拷贝数分享	预测靶向药物的有效性、肿瘤分子分型、判断预后	99个基因突变，未见基因重排，未见基因拷贝数变异
肿瘤突变负荷（TMB）	830个基因点突变、缺失、插入分析	预测免疫治疗药物疗效	51.64 muts/Mb
微卫星不稳定性（MSI）	3009个微卫星位点（MS）	预测免疫治疗药物疗效	微卫星不稳定型（MSI-H）
化疗单核苷酸多态性（SNP）位点检测	45个SNP位点	预测常见化疗药物有效性和毒副作用	详见检测结果详细解析
肿瘤遗传易感基因检测	148个肿瘤遗传易感基因	预测多种肿瘤的遗传风险	未检测到与肿瘤遗传易感性相关的明确致病突变

Please choose a citation manager

Content to export

A case of surgical resection complete pathological response after neoadjuvant immunotherapy for microsatellite instability-high colon cancer

RichHTML

PDF (PC)

Knowledge